We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Beam Therapeutics Inc. (BEAM) - $25 value - yours FREE >>
Editas Medicine, Inc. (EDIT) - $25 value - yours FREE >>
Intellia Therapeutics, Inc. (NTLA) - $25 value - yours FREE >>
Image: Bigstock
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
Editas Medicine, Inc. (EDIT - Free Report) has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.
Last month, the company announced initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10.
Preliminary results from the study were based on safety and efficacy data from the first two cohorts – the adult low-dose cohort and the adult mid-dose cohort.
In June 2021, Editas started enrollment in the first of two planned pediatric cohorts in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating LCA10. Treatment in the adult high-dose cohort is currently ongoing while treatment in the pediatric mid-dose cohort has just begun.
This apart, Editas has commenced the phase I/II RUBY study to assess the safety and efficacy of another pipeline candidate, EDIT-301, for treating sickle cell disease. The company plans to dose the first patient in the RUBY study by the end of 2021.
Editas also plans to submit an investigational new drug filing to the FDA to begin clinical studies on EDIT-301 for the treatment of beta-thalassemia by 2021-end.
We note that Editas has no approved product in its portfolio at the moment. Therefore, successful development of EDIT-101, along with other pipeline candidates, remains in key focus for the company.
Stiff competition remains a headwind as several other companies like CRISPR Therapeutics (CRSP - Free Report) , Intellia Therapeutics (NTLA - Free Report) and Beam Therapeutics (BEAM - Free Report) are also engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology. Moreover, Editas’ pipeline candidates are in early-stage development and years away from commercialization. Hence, any regulatory setbacks for the pipeline candidates will be a major setback for the company.